Roche Canada, pan-Canadian Pharmaceutical Alliance complete negotiations for VABYSMO to treat Neovascular neovascular AMD, DME

VABYSMO is a humanized bispecific immunoglobulin G1(IgG1) antibody that acts through inhibition of both Ang-2 and vascular endothelial growth factor A (VEGF-A).;

Published On 2023-05-30 12:16 GMT | Update On 2023-05-30 12:16 GMT

Mississauga: Hoffmann-La Roche Limited (Roche Canada) has announced that it has successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for VABYSMO (faricimab injection), indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD) and diabetic macular edema (DME), two of the leading causes of vision loss among Canadians.

“Securing a letter of intent with the pCPA for VABYSMO is incredible news for patients and the vision loss community,” said Larissa Moniz, Director, Research and Mission Programs, Fighting Blindness Canada. “We encourage the provinces to recognize the benefit that VABYSMO can bring to nAMD and DME patients, and prioritize public access for eligible Canadians.”

VABYSMO is the first treatment for wet AMD and DME in Canada that acts by targeting both VEGF-A and Ang-2, two key drivers of vascular instability that have been associated with vision-threatening retinal conditions. This unique dual MoA is made possible by Roche’s antibody engineering expertise.

“This milestone is a critical step towards providing access to VABYSMO for Canadians living with vision loss from nAMD and DME,” said Varun Chaudhary, Chief of Ophthalmology and Professor of Surgery, Hamilton Regional Eye Institute, McMaster University. “VABYSMO has demonstrated promising results in terms of efficacy, safety and durability of effect for both these diseases, and expedited public access for Canadians in need of this treatment is of paramount importance.”

VABYSMO was reviewed and positively recommended by Canada’s Health Technology Assessment bodies, including The Canadian Agency for Drugs and Technologies in Health (CADTH) in the fall of 2022, as well as Institut national d'excellence en santé et en services sociaux (INESSS) earlier in 2023, for the treatment of nAMD and DME.

"As a next step, Roche Canada is committed to continuing to work with other provincial jurisdictions to make VABYSMO available as soon as possible through public drug plans," the release stated.

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Roche Canada, pan-Canadian Pharmaceutical Alliance complete negotiations for VABYSMO to treat Neovascular neovascular AMD, DME

VABYSMO is a humanized bispecific immunoglobulin G1(IgG1) antibody that acts through inhibition of both Ang-2 and vascular endothelial growth factor A (VEGF-A).;

Similar News

EMA Committee approves update to Novo Nordisk Rybelsus label to reflect cardiovascular benefits

Aurobindo Pharma arm incorporates new wholly owned subsidiary in Malaysia

Natco Pharma gets USFDA EIR for Kothur Pharma division

Roche to acquire 89bio for up to USD 3.5 billion

Lupin bags USFDA approval for Multiple myeloma treatment

Biocon Biologics wins USFDA nod for Bosaya and Aukelso, Denosumab Biosimilars

Cocrystals of Approved APIs to Be Treated as New Drugs, Clarifies CDSCO

India ranks among top global contributors in adverse event reporting: DCGI